Gilead Sciences
GILD
$130.21
-0.82%
Gilead Sciences is a biopharmaceutical company that develops and markets therapies for life-threatening infectious diseases, with a core focus on HIV and hepatitis B and C, and is expanding into oncology through acquisitions such as Kite and Immunomedics. As a market leader in HIV treatment and prevention, Gilead holds a dominant position with a portfolio that includes blockbuster drugs like Biktarvy and Descovy, and it is leveraging its expertise to build a growing oncology franchise. The current investor narrative centers on Gilead's aggressive M&A strategy, including the $7.8 billion acquisition of Arcellx and a $3 billion deal with Tubulis, which aims to bolster its oncology pipeline but has raised concerns about near-term earnings dilution and integration risks. Additionally, recent news of a failed Trodelvy-Keytruda lung cancer trial has cast a shadow over the oncology growth story, while promising HIV data and a strong balance sheet provide a counterbalance.…
GILD
Gilead Sciences
$130.21
Related headlines
Investment Opinion: Should I buy GILD Today?
Gilead is rated a Buy based on its attractive valuation, strong cash flow, and potential for pipeline-driven growth. The consensus analyst recommendation is 'Buy' with an average target price of $157.15, implying a 20.7% upside from the current price of $130.21. The stock trades at a forward P/E of 13.54x, a discount to the industry average of 22x, and offers a dividend yield of 2.62%.
Sign up to view all
GILD 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Gilead's valuation is attractive, but the decelerating growth and recent pipeline failure temper enthusiasm. The stock's low beta of 0.343 suggests it is less volatile than the market, but it also underperformed the S&P 500 over the past year. The key factors point to a balanced risk-reward, with the potential for upside if oncology pipeline succeeds, but downside if further setbacks occur. An upgrade to bullish would require evidence of accelerating revenue growth or positive late-stage data, while a downgrade would follow additional trial failures or margin compression.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Gilead Sciences's 12-month outlook, with a consensus price target around $157.15 and implied upside of +20.7% versus the current price.
Average Target
$157.15
0 analysts
Implied Upside
+20.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$120 - $180
Analyst target range
Gilead is covered by 27 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.69 (where 1 is Strong Buy and 5 is Sell). The average target price is $157.15, implying a 20.7% upside from the current price of $130.21, while the low target of $120 suggests a 7.8% downside and the high target of $180 implies a 38.2% upside. The wide range between low and high targets indicates significant uncertainty about the company's pipeline and M&A strategy, but the recent upgrades from HSBC (Hold to Buy) and Maxim Group (Hold to Buy) suggest improving sentiment. The consensus leans bullish, but the low target suggests some analysts see risks from pipeline failures and integration challenges.
Bulls vs Bears: GILD Investment Factors
Gilead presents a mixed picture: its dominant HIV franchise and strong cash flow provide a stable foundation, while its aggressive M&A and pipeline expansion offer growth optionality. However, decelerating revenue growth, a failed oncology trial, and high leverage introduce significant risks. Currently, the bearish arguments hold slightly more weight due to the recent trial failure and slowing growth, but the attractive valuation and analyst upside suggest a balanced risk-reward. The key tension is whether the oncology pipeline can successfully diversify revenue and offset HIV deceleration, which will determine the stock's long-term trajectory.
Bullish
- Dominant HIV franchise with strong growth: HIV products generated $5.03 billion in Q1 2026, representing over 70% of total product sales. Biktarvy and Descovy continue to drive growth, with Q1 revenue up 4.4% YoY, providing a stable and recurring revenue base.
- Attractive valuation with 20.7% upside: GILD trades at a trailing P/E of 17.94x and forward P/E of 13.54x, a 18.5% discount to the industry average of 22x. The average analyst target of $157.15 implies a 20.7% upside from the current price of $130.21.
- Strong balance sheet and cash flow: Gilead generated $10.23 billion in trailing free cash flow and has a current ratio of 1.68. This financial strength supports its aggressive M&A strategy and a dividend yield of 2.62%.
- Expanding oncology pipeline via M&A: The $7.8 billion Arcellx acquisition and $3 billion Tubulis deal aim to strengthen the oncology portfolio, with Arcellx's CAR-T therapy for multiple myeloma expected to boost earnings from 2028. This diversifies revenue beyond HIV.
Bearish
- Revenue growth decelerating: Q1 2026 revenue growth of 4.4% YoY is a slowdown from 6.7% in Q4 2025 and 11.4% in Q3 2025. This deceleration raises concerns about the sustainability of growth, especially with HIV facing pricing pressures.
- Failed Trodelvy-Keytruda trial: The termination of the Trodelvy-Keytruda lung cancer trial in June 2026 is a significant setback for the oncology growth story. It casts doubt on Trodelvy's potential and may lead to reduced sales forecasts.
- High debt and integration risks: Debt-to-equity ratio of 1.08 indicates significant leverage. The aggressive M&A spree, including the $7.8B Arcellx deal, increases integration risk and could dilute near-term earnings.
- Stock underperforming market: GILD is down 8.27% over the last six months and has underperformed the S&P 500 by 16.23% over the same period. The stock is trading at 41.4% of its 52-week range, indicating weak momentum.
GILD Technical Analysis
Gilead's stock is currently in a recovery phase after a significant pullback, with the price at $130.21 as of July 31, 2026, up 15.96% over the past year but down 8.27% over the last six months. The stock is trading at 41.4% of its 52-week range (between $108.46 low and $157.29 high), indicating it is closer to the lower end of its range, which could suggest a value opportunity or reflect lingering bearish sentiment. The 52-week high was reached in February 2026, and the subsequent decline has been steep, with the stock losing 17.2% from that peak, but the recent stabilization above $130 suggests a potential bottoming process.
Beta
0.34
0.34x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$108-$157
Price range past year
Annual Return
+16.0%
Cumulative gain past year
| Period | GILD Return | S&P 500 |
|---|---|---|
| 1m | +3.4% | +0.3% |
| 3m | -1.1% | +4.0% |
| 6m | -8.3% | +8.3% |
| 1y | +16.0% | +20.2% |
| ytd | +7.1% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GILD Fundamental Analysis
Gilead's revenue trajectory shows modest growth, with Q1 2026 revenue of $6.96 billion, up 4.4% year-over-year, but this is a deceleration from the 6.7% growth seen in Q4 2025 and the 11.4% growth in Q3 2025. The growth is primarily driven by HIV products, which contributed $5.03 billion in Q1, while oncology products like Trodelvy ($402 million) and cell therapy ($482 million) are growing but remain a smaller portion of the mix. The company's reliance on HIV for over 70% of product sales highlights concentration risk, but the strong performance of newer HIV drugs like Biktarvy provides a stable base.
Quarterly Revenue
$7.0B
2026-03
Revenue YoY Growth
+4.4%
YoY Comparison
Gross Margin
79.2%
Latest Quarter
Free Cash Flow
$10.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GILD Overvalued?
Given Gilead's positive net income, the trailing P/E ratio of 17.94x is the primary valuation metric, with a forward P/E of 13.54x, implying the market expects earnings growth of 32.5% over the next year. The PEG ratio of 0.01 is exceptionally low, but this is distorted by the extremely high EPS growth estimate of 12.96, which may not be sustainable. Compared to the industry average P/E of 22x (based on available data), Gilead trades at a 18.5% discount, which could be justified by its slower growth relative to biotech peers but also reflects the market's skepticism about its pipeline.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt-to-equity ratio of 1.08, which could strain cash flows if interest rates rise or if acquisitions fail to generate expected returns. The company's reliance on HIV for over 70% of product sales creates concentration risk, and any pricing pressure or loss of market share could significantly impact revenue. Additionally, the aggressive M&A strategy, including the $7.8 billion Arcellx acquisition, may lead to integration challenges and potential earnings dilution in the near term. However, Gilead's strong free cash flow of $10.23 billion and current ratio of 1.68 provide a buffer against these risks.
FAQ
Key risks include: 1) Financial risk from high debt (D/E of 1.08) and potential earnings dilution from M&A. 2) Competitive risk in HIV from new entrants and pricing pressure. 3) Pipeline risk, as evidenced by the Trodelvy-Keytruda trial failure. 4) Macro risk, though the low beta of 0.343 suggests lower market sensitivity. The most severe risk is a major pipeline failure, which could lead to a -20% or more decline.
The 12-month forecast is mixed. The bull case (25% probability) targets $157-$180, driven by pipeline successes. The base case (50% probability) targets $140-$157, assuming steady HIV growth and modest oncology contributions. The bear case (25% probability) targets $108-$120, if further setbacks occur. The most likely scenario is the base case, with the stock reaching the average analyst target of $157.15.
GILD is undervalued relative to its peers and its own history. The trailing P/E of 17.94x and forward P/E of 13.54x are below the industry average of 22x. The PEG ratio of 0.01 is extremely low, though it is distorted by high EPS growth estimates. The market appears to be pricing in skepticism about the oncology pipeline and growth sustainability. If the pipeline delivers, the stock could re-rate higher.
GILD is a reasonable buy for investors seeking a value stock with a dividend and moderate growth. The stock trades at a forward P/E of 13.54x, a discount to the industry average of 22x, and offers a 20.7% upside to the average analyst target of $157.15. However, the recent failure of the Trodelvy-Keytruda trial and decelerating revenue growth are concerns. For long-term investors with a tolerance for pipeline risk, GILD could be a good addition, but for those seeking high growth, other biotech names may be more suitable.
GILD is more suitable for long-term investment due to its stable HIV business, dividend yield, and potential pipeline catalysts. The low beta (0.343) indicates lower volatility, making it less attractive for short-term trading. A minimum holding period of 3-5 years is recommended to allow the oncology pipeline to mature and for M&A integrations to bear fruit. Short-term traders may find limited opportunities given the stock's recent underperformance.